{"id":61047,"date":"2024-02-28T07:22:30","date_gmt":"2024-02-28T07:22:30","guid":{"rendered":"https:\/\/medsname.com\/hytrin\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"hytrin","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/hytrin\/","title":{"rendered":"Hytrin"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Rychl\u00e1 odpov\u011b\u010f \u2014 Co je Hytrin?<\/h3>\n

Hytrin<\/strong> je 1 \/ 2 \/ 5 mg Terazosin tableta<\/strong> od spole\u010dnosti AbbVie \u2014 dlouhodob\u011b p\u016fsob\u00edc\u00ed selektivn\u00ed antagonista alfa-1 adrenergn\u00edho receptoru (chinazolin)<\/strong>, p\u016fsob\u00ed na postsynaptick\u00e9 alfa-1 adrenergn\u00ed receptory na hladk\u00e9m svalstvu tepen a na hladk\u00e9m svalstvu prostaty\/\u00fast\u00ed mo\u010dov\u00e9ho m\u011bch\u00fd\u0159e<\/strong>. Terazosin byl uveden na trh spole\u010dnost\u00ed Abbott (nyn\u00ed AbbVie) v roce 1987 jako Hytrin<\/strong> \u2014 vyvinut jako dlouhodob\u011bji p\u016fsob\u00edc\u00ed n\u00e1stupce prazosinu s polo\u010dasem 12 hodin, kter\u00fd umo\u017e\u0148uje jednodenn\u00ed d\u00e1vkov\u00e1n\u00ed. Strukturn\u011b jde o bl\u00edzk\u00fd chinazolinov\u00fd analog prazosinu. V 90. letech a na po\u010d\u00e1tku 21. stolet\u00ed \u0161iroce pou\u017e\u00edv\u00e1n pro benign\u00ed hyperplazii prostaty (BPH) a jako dopl\u0148kov\u00e9 antihypertenzivum; \u010d\u00e1ste\u010dn\u011b vytla\u010den prostaticky selektivn\u00edmi alfa-1A blok\u00e1tory (tamsulosin, silodosin) pro pou\u017eit\u00ed pouze u BPH, ale zachov\u00e1v\u00e1 si silnou pozici tam, kde sou\u010dasn\u00e1 hypertenze \u010din\u00ed neselektivn\u00ed alfa-blok\u00e1tor vhodn\u00fdm. Polo\u010das 12 hodin (vhodn\u00e9 jednodenn\u00ed d\u00e1vkov\u00e1n\u00ed); n\u00e1stup \u00fa\u010dinku 1-2 hodiny; vrchol 1-2 hodiny; symptomatick\u00fd p\u0159\u00ednos u BPH obvykle za 2-4 t\u00fddny. Hlavn\u00ed indikace: benign\u00ed hyperplazie prostaty, rezistentn\u00ed hypertenze jako dopl\u0148kov\u00fd prost\u0159edek<\/strong>. Typick\u00e9 d\u00e1vkov\u00e1n\u00ed: Hypertenze:<\/strong> za\u010dn\u011bte s 1 mg p\u0159ed span\u00edm (riziko fenom\u00e9nu prvn\u00ed d\u00e1vky), titrujte ka\u017ed\u00fdch 1-2 t\u00fddny a\u017e na 5-20 mg\/den. Del\u0161\u00ed polo\u010das ve srovn\u00e1n\u00ed s prazosinem umo\u017e\u0148uje praktick\u00e9 jednodenn\u00ed d\u00e1vkov\u00e1n\u00ed. Nen\u00ed l\u00e9kem prvn\u00ed volby p\u0159i hypertenzi.<\/strong> Studie ALLHAT p\u0159ed\u010dasn\u011b ukon\u010dila rameno s doxazosinem kv\u016fli nadm\u011brn\u00e9mu v\u00fdskytu srde\u010dn\u00edho selh\u00e1n\u00ed; u terazosinu se p\u0159edpokl\u00e1d\u00e1 stejn\u00e1 t\u0159\u00eddn\u00ed obava. Vyhrazeno pro pou\u017eit\u00ed ve \u010dtvrt\u00e9\/p\u00e1t\u00e9 linii, zejm\u00e9na tam, kde koexistuje BPH. V\u017edy pod\u00e1vejte prvn\u00ed d\u00e1vku p\u0159ed span\u00edm<\/strong> \u2014 fenom\u00e9n \u201cprvn\u00ed d\u00e1vky\u201d zp\u016fsobuje z\u00e1va\u017enou ortostatickou hypotenzi v po\u010d\u00e1te\u010dn\u00edch hodin\u00e1ch. Nen\u00ed prvn\u00ed volbou antihypertenziv (obavy z t\u0159\u00eddy ALLHAT) \u2014 vyhrazeno pro \u010dtvrtou\/p\u00e1tou linii, zejm\u00e9na tam, kde se vyskytuje BPH. U v\u011bt\u0161iny hypertonik\u016f modern\u00ed l\u00e9\u010dba za\u010d\u00edn\u00e1 ACE inhibitorem\/ARB, blok\u00e1torem kalciov\u00fdch kan\u00e1l\u016f, thiazidem a spironolaktonem, ne\u017e se p\u0159istoup\u00ed k alfa-blok\u00e1toru nebo centr\u00e1ln\u011b p\u016fsob\u00edc\u00edmu \u010dinidlu.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n

Co je Hytrin?<\/h2>\n

Hytrin jsou peror\u00e1ln\u00ed tablety Terazosinu 1\/2\/5 mg od spole\u010dnosti AbbVie, dod\u00e1van\u00e9 v balen\u00ed po 30-180 tablet\u00e1ch. Terazosin byl uveden na trh spole\u010dnost\u00ed Abbott (nyn\u00ed AbbVie) v roce 1987 jako Hytrin<\/strong> \u2014 vyvinut jako dlouhodob\u011bji p\u016fsob\u00edc\u00ed n\u00e1stupce prazosinu s polo\u010dasem 12 hodin, kter\u00fd umo\u017e\u0148uje jednodenn\u00ed d\u00e1vkov\u00e1n\u00ed. Strukturn\u011b jde o bl\u00edzk\u00fd chinazolinov\u00fd analog prazosinu. V 90. letech a na po\u010d\u00e1tku 21. stolet\u00ed \u0161iroce pou\u017e\u00edv\u00e1n pro benign\u00ed hyperplazii prostaty (BPH) a jako dopl\u0148kov\u00e9 antihypertenzivum; \u010d\u00e1ste\u010dn\u011b vytla\u010den prostaticky selektivn\u00edmi alfa-1A blok\u00e1tory (tamsulosin, silodosin) pro pou\u017eit\u00ed pouze u BPH, ale zachov\u00e1v\u00e1 si silnou pozici tam, kde sou\u010dasn\u00e1 hypertenze \u010din\u00ed neselektivn\u00ed alfa-blok\u00e1tor vhodn\u00fdm.<\/p>\n

Jak Terazosin funguje<\/h2>\n

Terazosin p\u016fsob\u00ed na postsynaptick\u00e9 alfa-1 adrenergn\u00ed receptory na hladk\u00e9m svalstvu tepen a na hladk\u00e9m svalstvu prostaty\/\u00fast\u00ed mo\u010dov\u00e9ho m\u011bch\u00fd\u0159e<\/strong>. N\u00e1sledn\u00e9 \u00fa\u010dinky:<\/p>\n

    \n
  • Vazodilatace arteri\u00e1ln\u00ed a ven\u00f3zn\u00ed<\/strong> \u2014 blok\u00e1da alfa-1 receptor\u016f na c\u00e9vn\u00ed hladk\u00e9 svalovin\u011b sni\u017euje syst\u00e9movou c\u00e9vn\u00ed rezistenci; ven\u00f3zn\u00ed dilatace sni\u017euje preload<\/li>\n
  • Sn\u00ed\u017een\u00fd tonus hladk\u00e9 svaloviny hrdla mo\u010dov\u00e9ho m\u011bch\u00fd\u0159e a prostaty<\/strong> \u2014 zlep\u0161uje mo\u010dov\u00fd pr\u016ftok u BPH (dominantn\u00ed klinick\u00fd \u00fa\u010dinek u XL\/dlouhodob\u011b p\u016fsob\u00edc\u00edch forem)<\/li>\n
  • Zlep\u0161en\u00fd lipidov\u00fd profil<\/strong> \u2014 m\u00edrn\u00e9 sn\u00ed\u017een\u00ed LDL a triglycerid\u016f, mal\u00e9 zv\u00fd\u0161en\u00ed HDL; metabolicky odli\u0161n\u00e9 od thiazid\u016f a betablok\u00e1tor\u016f<\/li>\n
  • Zlep\u0161en\u00e1 citlivost na inzulin<\/strong> v n\u011bkter\u00fdch studi\u00edch \u2014 argument pro alfa-blok\u00e1tory u hypertonik\u016f s metabolick\u00fdm syndromem nebo diabetem 2. typu<\/li>\n
  • \u017d\u00e1dn\u00fd p\u0159\u00edm\u00fd vliv na renin nebo elektrolyty<\/strong> \u2014 drasl\u00edk, sod\u00edk a kreatinin nejsou ovlivn\u011bny (na rozd\u00edl od diuretik a blok\u00e1tor\u016f RAAS)<\/li>\n
  • Reflexn\u00ed tachykardie<\/strong> je ve srovn\u00e1n\u00ed s p\u0159\u00edm\u00fdmi vazodilat\u00e1tory (hydralazin, minoxidil) otupen\u00fd kv\u016fli ur\u010dit\u00e9 centr\u00e1ln\u00ed sympatick\u00e9 zp\u011btn\u00e9 vazb\u011b, ale st\u00e1le se vyskytuje p\u0159i zah\u00e1jen\u00ed l\u00e9\u010dby<\/li>\n<\/ul>\n

    Schv\u00e1len\u00e9 a v\u011bdecky podlo\u017een\u00e9 indikace<\/h2>\n
      \n
    • Benign\u00ed hyperplazie prostaty, rezistentn\u00ed hypertenze jako dopl\u0148kov\u00fd prost\u0159edek<\/strong><\/li>\n
    • Benign\u00ed hyperplazie prostaty<\/strong> \u2014 hlavn\u00ed indikace; v\u00fdhoda jednodenn\u00edho d\u00e1vkov\u00e1n\u00ed<\/li>\n
    • Rezistentn\u00ed hypertenze<\/strong> jako dopln\u011bk \u010dtvrt\u00e9\/p\u00e1t\u00e9 linie, zejm\u00e9na p\u0159i sou\u010dasn\u00e9m v\u00fdskytu BPH<\/li>\n<\/ul>\n

      Kl\u00ed\u010dov\u00e9 d\u016fkazy z klinick\u00fdch studi\u00ed:<\/strong> Studie hodnocen\u00ed komunity HYTRIN (HYCAT, 1996)<\/strong> \u2014 terazosin zlep\u0161il IPSS o 37 % u 2 084 mu\u017e\u016f se symptomatickou BPH b\u011bhem 1 roku. VA Cooperative BPH Trial (Lepor, NEJM 1996)<\/strong> \u2014 terazosin + finasterid nebyl lep\u0161\u00ed ne\u017e samotn\u00fd terazosin u mu\u017e\u016f s men\u0161\u00ed prostatou, co\u017e p\u0159edznamenalo zji\u0161t\u011bn\u00ed studie MTOPS, \u017ee kombinovan\u00e1 terapie pom\u00e1h\u00e1 u v\u011bt\u0161\u00edch prostat. ALLHAT doxazosinov\u00e1 v\u011btev (2000)<\/strong> \u2014 sign\u00e1l na \u00farovni t\u0159\u00eddy u srde\u010dn\u00edho selh\u00e1n\u00ed.<\/p>\n

      D\u00e1vkov\u00e1n\u00ed Hytrinu<\/h2>\n

      Z\u00e1kladn\u00ed d\u00e1vka:<\/strong> Hypertenze:<\/strong> za\u010dn\u011bte s 1 mg p\u0159ed span\u00edm (riziko fenom\u00e9nu prvn\u00ed d\u00e1vky), titrujte ka\u017ed\u00fdch 1-2 t\u00fddny a\u017e na 5-20 mg\/den. Del\u0161\u00ed polo\u010das ve srovn\u00e1n\u00ed s prazosinem umo\u017e\u0148uje praktick\u00e9 jednodenn\u00ed d\u00e1vkov\u00e1n\u00ed. Nen\u00ed l\u00e9kem prvn\u00ed volby p\u0159i hypertenzi.<\/strong> Studie ALLHAT p\u0159ed\u010dasn\u011b ukon\u010dila rameno s doxazosinem kv\u016fli nadm\u011brn\u00e9mu v\u00fdskytu srde\u010dn\u00edho selh\u00e1n\u00ed; u terazosinu se p\u0159edpokl\u00e1d\u00e1 stejn\u00e1 t\u0159\u00eddn\u00ed obava. Vyhrazeno pro pou\u017eit\u00ed ve \u010dtvrt\u00e9\/p\u00e1t\u00e9 linii, zejm\u00e9na tam, kde koexistuje BPH.<\/p>\n

      Dal\u0161\u00ed indikace:<\/strong> 1 mg at bedtime initially, titrating by 1 mg every 3-5 days to clinical effect. Typical effective dose 2-10 mg at bedtime; some patients require 15-20 mg. Evidence base: Raskind and Peskind RCTs (2003-2013) showed significant reduction in nightmare frequency and improvement in sleep architecture, though the larger 2018 PACT trial was negative \u2014 enthusiasm tempered but use remains common when CBT-I and trauma-focused psychotherapy are inadequate.<\/strong> za\u010dn\u011bte s 1 mg p\u0159ed span\u00edm, titrujte na 5-10 mg jednou denn\u011b b\u011bhem 2-4 t\u00fddn\u016f. D\u00e1vku pod\u00e1vejte p\u0159ed span\u00edm trvale, aby se minimalizovaly ortostatick\u00e9 \u00fa\u010dinky. \u00daleva od p\u0159\u00edznak\u016f je obvykle patrn\u00e1 za 4-6 t\u00fddn\u016f; pokud je nedostate\u010dn\u00e1, p\u0159ejd\u011bte na nebo p\u0159idejte prostatov\u011b selektivn\u00ed blok\u00e1tor alfa-1A (tamsulosin) nebo inhibitor 5-alfa-redukt\u00e1zy (finasterid) u v\u011bt\u0161\u00edch prostat (>40 g).<\/p>\n

      Pod\u00e1v\u00e1n\u00ed:<\/strong> u\u017e\u00edvejte jednou denn\u011b p\u0159ed span\u00edm. Potrava v\u00fdznamn\u011b neovliv\u0148uje vst\u0159eb\u00e1v\u00e1n\u00ed.<\/p>\n

      Monitorovac\u00ed pl\u00e1n:<\/strong><\/p>\n